Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04480645 · ClinicalTrials.gov registry record · Early Phase 1
CivaDerm(TM) Surface Therapy Pilot Study
A Early Phase 1 study of Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin, sponsored by CivaTech Oncology.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04480645 is a Early Phase 1 study of Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin that is actively recruiting participants, run by CivaTech Oncology. The registered enrollment target is 10 participants, below the 104-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04480645, a Early Phase 1 study of Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin, is actively recruiting participants, sponsored by CivaTech Oncology.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine the usefulness of new brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit basal cell and squamous cell carcinoma patients by providing conformal radiation therapy to the surface of the skin.
Conditions Studied
Interventions
- DEVICE CivaDerm
Study Locations (1)
North Carolina
- CivaDerm Oncology PLLC - Morrisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04480645
The ClinicalTrials.gov registry entry for NCT04480645 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (90% lower). The listed sponsor is CivaTech Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which CivaDerm is the first listed.
NCT04480645 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04480645 about?
NCT04480645 is a clinical study titled "CivaDerm(TM) Surface Therapy Pilot Study". This is a pilot study to determine the usefulness of new brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit basal cell and squamous cell carcinoma patients by providing conformal radiation therapy to the surface of the...
What is the current status of trial NCT04480645?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-05-01. Estimated completion is 2026-04-30.
What conditions does trial NCT04480645 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma, Squamous Cell Carcinoma of the Skin.
What interventions are being tested in trial NCT04480645?
The interventions under investigation include: CivaDerm (DEVICE).
Who is sponsoring clinical trial NCT04480645?
This trial is sponsored by CivaTech Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04480645 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
RECRUITING · Phase 1
-
Investigation of Standard Excision Surgical Margins Using Two Photon Fluorescence Microscopy
RECRUITING · NA
Explore more on PlainTrial
Basal Cell Carcinoma
All registered trials for this condition
Squamous Cell Carcinoma of the Skin
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.